<DOC>
	<DOCNO>NCT01922375</DOCNO>
	<brief_summary>This study design evaluate efficacy safety Naftopidil Korean male patient low urinary tract symptom associate benign prostatic hyperplasia . The investigator hypothesize Naftopidil come onto marcket Japan would effect improvement void storage difficulty . Design : Placebo-controlled , Randomized , Double-blind , Double-dummy , Parallel group , Fixed dose design</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety Naftopidil Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Naftopidil</mesh_term>
	<criteria>Male patient age 4 year diagnose BPH subject uncontrolled blood pressure subject hepatic renal dysfunction subject prostate cancer Had treatment BPH use alpha receptor antagonist within 2 week</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>